Effect of metformin on progression-free survival outcomes in patients with advanced or metastatic HR+, HER2-breast cancer: subgroup analysis of STEPAUT

被引：0
|
作者：
Egle, D. [1 ]
Marth, C. [1 ]
Steger, G. [2 ,3 ]
Bartsch, R. [2 ,3 ]
Pfeiler, G. [4 ]
Greil, R. [5 ]
Helfgott, R. [6 ]
Oehler, L. [7 ]
Hennebelle, M. [8 ]
Gnant, M. [3 ,9 ]
机构：
[1] Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria
[2] Med Univ Vienna, Dept Oncol, Vienna, Austria
[3] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
[4] Med Univ Vienna, Dept Gynecol & Gynecol Oncol, Vienna, Austria
[5] Med Univ Salzburg, Dept Oncol, Salzburg, Austria
[6] Hosp Sisters Char, Dept Surg, Linz, Austria
[7] St Josephs Hosp Vienna, Dept Oncol, Vienna, Austria
[8] Novartis Pharma GmbH, Vienna, Austria
[9] Med Univ Vienna, Dept Surg, Vienna, Austria
来源：
BREAST | 2017年 / 32卷
关键词：
D O I：
10.1016/S0960-9776(17)30115-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P014
引用
收藏
页码：S26 / S27
页数：2
相关论文
共 50 条
  • [1] Treatment of metastatic HR+, HER2-Breast Cancer with Abemaciclib Significant Prolongation of progression-free and Overall Survival - also in Subgroups
    Ruedesheim, Sabine M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (09) : 485 - 485
  • [2] Dalpiciclib Extends Progression-Free Survival in HR+/HER2-Advanced Breast Cancer
    不详
    [J]. ONCOLOGIST, 2021, 26 : S9 - S10
  • [3] Composite biomarkers for the prediction of progression-free survival with CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer
    Witkiewicz, Agnieszka
    Wang, Jianxin
    Knudsen, Erik
    Levine, Ellis
    O'Connor, Tracey
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [4] Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer
    Forsythe, Anna
    Chandiwana, David
    Barth, Janina
    Thabane, Marroon
    Baeck, Johan
    Tremblay, Gabriel
    [J]. BREAST CANCER-TARGETS AND THERAPY, 2018, 10 : 69 - 78
  • [5] The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
    Sarina, Piha-Paul
    Xu, Binghe
    Fan, Ying
    Yuan, Yuan
    Lavasani, Sayeh
    Mortimer, Joanne
    Goel, Sanjay
    Tsimberidou, Apostolia
    Ibrahim, Nuhad
    Abouharb, Sausan
    Barcenas, Carlos
    Lheme, Adaeze
    Karp, Daniel
    Ahnert, Jordi Rodon
    Dumbrava, Ecaterina
    Fan, Jean
    Peng, Peng
    Sun, Caixia
    Wang, Hui
    Hennessy, Katie
    Fu, Ximei
    Xu, Ruolan
    Ni, Shumao
    Wu, Frank
    Meric-Bernstam, Funda
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [6] A new era of improving progression-free survival in HR+, HER2- advanced breast cancer with dual blockade
    Jerusalem, G.
    Bachelot, T.
    Barrios, C.
    Andre, F.
    Neven, P.
    Di Leo, A.
    Janni, W.
    de Boer, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S185 - S185
  • [7] A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2- advanced breast cancer
    Jerusalem, Guy
    Bachelot, Thomas
    Barrios, Carlos
    Neven, Patrick
    Di Leo, Angelo
    Janni, Wolfgang
    de Boer, Richard
    [J]. CANCER TREATMENT REVIEWS, 2015, 41 (02) : 94 - 104
  • [8] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2-Breast Cancer
    Kang, Connie
    [J]. TARGETED ONCOLOGY, 2024, 19 (02) : 289 - 296
  • [9] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [10] Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/ HER2- metastatic breast cancer?
    Forsythe, Anna
    Chandiwana, David
    Barth, Janina
    Thabane, Marroon
    Baeck, Johan
    Shor, Anastasiya
    Tremblay, Gabriel
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1015 - 1025
12345